Your Article Summary
See Latest ArticlesGiant cell tumour of bone
Current Opinion in Oncology, 06/18/09
Thomas DM et al. - In a study to determine new treatment options for pts with unresectable giant cell tumour of bone (GCT), it appears that denosumab presents a new treatment option for pts with previously untreatable GCT. The eventual role of denosumab and other targeted agents in the treatment of GCT and related disorders is currently the subject of active study.
Methods- Recent discoveries have identified a key role for the osteoclast differentiation factor, receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL), in the genesis of GCT.
- Development of the fully human monoclonal antibody to RANKL, denosumab, has led to a clinical trial in unresectable GCT.
- This study demonstrated an 86% response rate, with comparable evidence of clinical benefit, and was well tolerated.
- Other pathways that may present targets for therapy include the hypoxia-angiogenesis axis and the colony stimulating factor 1 receptor.
Related Articles
Endoprosthetic reconstruction of the distal tibia and ankle joint after resection of primary bone tumours
The Journal of Bone and Joint Surgery (British Volume), 10/13/09
Relevance Score: 82%
Biological reconstruction after resection of bone tumours around the knee
The Journal of Bone and Joint Surgery (British Volume), 10/01/09
Relevance Score: 82%
Giant Cell Tumour of the Distal Radius: Wide Resection and Reconstruction by Non-vascularised Proximal Fibular Autograft
Annals, Academy of Medicine, Singapore, 11/03/09
Relevance Score: 81%
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours
Histopathology, 10/15/09
Relevance Score: 81%
The early results of joint-sparing proximal tibial replacement for primary bone tumours, using extracortical plate fixation
The Journal of Bone and Joint Surgery (British Volume), 10/09/09
Relevance Score: 80%
Today in Bone/Cartilage...keeping you current
Receive free subspecialty "5-minute updates" via email
Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1
British Journal of Cancer, 12/18/09
Epidermal growth factor signalling and bone metastasis
British Journal of Cancer, 12/18/09
Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis
Oncogene, 12/17/09